Novo Nordisk's parent to buy Catalent for $16.5 bln to boost Wegovy supply
Published
Published
The sale of listed contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance for big pharma..
CTLT stock is up with heavy trading on the news Catalent (NYSE:CTLT) stock is climbing higher on Monday after the company agreed to..